Key Points
Promising trials of a new antibiotic drug trademarked as Zaynich - meant to act against all major superbugs - has triggered a sharp run-up in the Wockhardt stock..
This is akin to the opportunity which diabetes drug Ozempic provided to its innovator Novo Nordisk on being the wonder drug for weight loss..
Wockhardt's founder chairman Habil Khorakiwala in his AGM speech has informed that the Zaynich drug is a proprietary new chemical entity and one-of-its-kind antibiotics discovered in the last 50 years..
The promise of a successful drug discovery by an Indian pharma company has led marquee investors such as Madhusudan Kela and Prashant Jain to invest in Wockhardt's QIP issue of 480 crore earlier in March..
Zaynich may well have the potential to be for Wockhardt what Ozempic turned out to be for the Novo Nordisk stock, but the moot question is how much to pre-empt the drug's success during the final trial phase...
